Table 2 Prognostic value of NUCB2 mRNA expression for the biochemical recurrence-free survival in univariate and multivariate analyses by Cox regression
From: Clinical significance of NUCB2 mRNA expression in prostate cancer
| Â | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
Covariant | Exp (B) | 95% CI | P value | Exp (B) | 95% CI | P value |
NUCB2 expression | 3.120 | 1.692–5.754 | <0.001 | 2.900 | 1.569–5.360 | 0.001 |
Gleason score | 1.703 | 1.280–2.265 | <0.001 | 1.663 | 1.250–2.211 | <0.001 |
Preoperative PSA | 1.241 | 0.705–2.188 | 0.454 |  |  |  |
Age | 1.068 | 0.804–1.419 | 0.650 |  |  |  |
Angiolymphatic invasion | 1.084 | 0.814–1.443 | 0.580 |  |  |  |
Surgical margin status | 1.017 | 0.709–1.459 | 0.925 |  |  |  |
PCa Stage | 1.090 | 0.921–1.291 | 0.316 |  |  |  |
Lymph node metastasis | 1.140 | 0.850–1.528 | 0.381 |  |  |  |
Seminal vesicle invasion | 1.505 | 1.132–2.003 | 0.005 | 1.410 | 1.060–1.876 | 0.018 |